A Real-world Survey on Treatment and Prognosis Following Primary Lung Cancer Development in Patients with Interstitial Lung Disease Undergoing Antifibrotic Therapy: A Multicenter Retrospective Study

A Real-world Survey on Treatment and Prognosis Following Primary Lung Cancer Development in Patients with Interstitial Lung Disease Undergoing Antifibrotic Therapy: A Multicenter Retrospective Study - A Real-world Survey on the Actual Situation Following Primary Lung Cancer Development in ILD Patients Receiving Antifibrotic Therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060497

Enrollment

500

Registered

2026-02-02

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer with interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age: 20 years or older 2. Patients diagnosed with any interstitial lung disease 3. Patients who have been on antifibrotic therapy for 3 months or longer 4. Patients diagnosed with primary lung cancer while receiving antifibrotic therapy

Exclusion criteria

Exclusion criteria: 1. Patients not receiving antifibrotic drugs for ILD 2. Patients with interstitial changes of 10% or less on chest HRCT (ILA patients) 3. Patients in which anti-fibrotic drugs for ILD were discontinued, followed by the development of primary lung cancer 4. Patients in which anti-fibrotic drugs were initiated after diagnosis of primary lung cancer 5. Patients in which anticancer drugs were administered for primary lung cancer prior to anti-fibrotic drug administration 6. Drug-induced ILD 7. Patients deemed unsuitable as study subjects by the principal investigator

Design outcomes

Primary

Measure	Time frame
Overall survival from the diagnosis of primary lung cancer	—

Countries

Japan

Contacts

Public ContactMotoyasu Kato

Juntendo University Graduate School of Medicine Department of Respiratory Medicine

mtkatou@juntendo.ac.jp0338133111

Outcome results